The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
about
5-alpha-reductase inhibitors for prostate cancer preventionPhosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasiaSerenoa repens for benign prostatic hyperplasiaFinasteride for benign prostatic hyperplasiaSerenoa repens for benign prostatic hyperplasia5alpha-reductase: history and clinical importanceCurrent medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitationsThe effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young menNew therapeutic strategies for the treatment of male lower urinary tract symptomsRecent advances in treatment for Benign Prostatic HyperplasiaKorean clinical practice guideline for benign prostatic hyperplasiaFixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasiaMetabolic syndrome, inflammation and lower urinary tract symptoms: possible translational linksPhosphodiesterase type 5 inhibitors for treating erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia: A comprehensive reviewThe many ways to make a luminal cell and a prostate cancer cellUpdate on medical therapy for male LUTSCombination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focusShort-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trialEjaculatory dysfunction in the treatment of lower urinary tract symptomsThe pathophysiology of delayed ejaculationEvidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasiaGenetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis.Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms.The effect of increasing doses of saw palmetto fruit extract on serum prostate specific antigen: analysis of the CAMUS randomized trialEffect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial.Recruitment of participants to a clinical trial of botanical therapy for benign prostatic hyperplasia.Redesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia.Moxibustion as an adjuvant for benign prostatic hyperplasia with lower urinary tract symptoms: a protocol for a parallel-group, randomised, controlled pilot trial.Testosterone and 17β-estradiol induce glandular prostatic growth, bladder outlet obstruction, and voiding dysfunction in male micePrevalence of low testosterone in aging men with benign prostatic hyperplasia: data from the Proscar Long-term Efficacy and Safety Study (PLESS).Free prostate-specific antigen provides more precise data on benign prostate volume than total prostate-specific antigen in korean populationEffects of long-term oral testosterone undecanoate therapy on urinary symptoms: data from a 1-year, placebo-controlled, dose-ranging trial in aging men with symptomatic hypogonadism.Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trials.Nanostructured systems containing babassu (Orbignya speciosa) oil as a potential alternative therapy for benign prostatic hyperplasia[Combined treatment of BPS with tamsulosin and finasteride : Literature review and prescription data].Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy.Silodosin for benign prostatic hyperplasia.Dropout in a longitudinal, cohort study of urologic disease in community men.Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment.A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.
P2860
Q22252970-4D6A51CE-0531-45DF-8BEB-7D06A0FE994EQ24199135-2F884684-692F-4ED6-89F4-C57EEB308116Q24202555-93EFFCCD-AC7F-40A8-AC74-CDF7D0E4234AQ24234464-D8187BA7-9E97-46C8-9445-BD75B36FCD65Q24241144-E4DE75E8-481C-456B-A936-F09433E1EC42Q24546176-80422AA0-3786-47A5-911E-5F1B828576F1Q24649617-B15B7EDA-A33A-49DF-89D2-E4D8184F78D8Q24658075-FD24205A-4FB0-40F2-B96E-31B39EE225B1Q26746138-65D0FF0A-2BAF-474C-9CBF-E477802D2081Q26766218-41A3587C-B9CB-45D9-892D-CC0807D0052EQ26766302-F76EE797-24C0-480C-B49B-6BD8F377B758Q26770425-3AB1DB8F-0D99-448C-9B4C-FC16FC8D84DCQ26782663-3EADC91C-6299-43BC-87EC-6D4AE28FEC2EQ26785752-492603F8-FD25-41D1-B020-233E35281911Q26797386-C1E525CA-76A2-4DA0-B43A-AA0716A10627Q26862710-11D481B2-4A71-4361-BDBA-B81CBFE58B79Q27008847-CE9C96BB-AE3D-4F9F-9CC1-BD2A4DAF2562Q27009177-1E723921-604F-4C4E-8435-7FF52B01DF02Q28073775-221DEFC8-736E-4FD0-9F8D-D5FDFAD6180FQ28074466-019C394C-2149-4B8C-A7D2-320E3D41AAC9Q28077954-AD277756-D09A-45A5-B975-7B6EAC55375DQ30234717-2F38DEBE-3815-4B93-9C4E-92FFD13152FBQ30249162-C6716DA4-E44A-4B0F-AA39-536A29E2ECA7Q30413910-D70E73D2-4147-4E69-958B-D6D7349FDFA0Q30424857-7CEB2ACC-21E7-4D23-9D39-1BF8B34BED0CQ30427093-BFE409A1-9565-4C53-87D8-8BC1606E655DQ30432603-23571D0D-F20C-4D0B-A31F-24157B8902A1Q30488666-E0377A3B-F957-4663-8F47-647181149456Q30525673-D177A7FB-B4B8-4A51-915E-78A5F0D2E27CQ30597556-A1216DE1-5212-49A1-BC41-2FF6A9599310Q30656133-DA6CC0B0-4B7B-4A30-B666-5AA8A8C4DC76Q30962192-E40AD4B9-F809-4732-8720-D7CF63559BB5Q31112168-243E5FC7-8C88-4F4B-A5D0-5D59476D1BC8Q31128985-2CDFAE95-2026-476B-88BF-E47287D0BE35Q31149371-F0DB16DD-8188-46CE-8493-21BF430FF288Q33156578-C683A335-21E6-40D7-A52E-CD8E049B7B6BQ33158241-300EEF27-5EBF-44C5-AB40-52381F841D1EQ33266615-74917FDC-AB6E-4377-8654-9C3F75C2B414Q33289952-F5D2574F-1CBA-485E-A70F-48C6B21DD41DQ33320106-22D0197B-D390-49B4-9D6E-ED2B9B2E2194
P2860
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
The long-term effect of doxazo ...... benign prostatic hyperplasia.
@en
The long-term effect of doxazo ...... benign prostatic hyperplasia.
@nl
type
label
The long-term effect of doxazo ...... benign prostatic hyperplasia.
@en
The long-term effect of doxazo ...... benign prostatic hyperplasia.
@nl
prefLabel
The long-term effect of doxazo ...... benign prostatic hyperplasia.
@en
The long-term effect of doxazo ...... benign prostatic hyperplasia.
@nl
P2093
P356
P1476
The long-term effect of doxazo ...... benign prostatic hyperplasia.
@en
P2093
Ananias Diokno
Christopher M Dixon
Claus G Roehrborn
Douglas F Milam
E David Crawford
Gary J Miller
Gerald L Andriole
Harris E Foster
Harry S Clarke
Herbert Lepor
P304
P356
10.1056/NEJMOA030656
P407
P577
2003-12-01T00:00:00Z